Our Teams

As the Chief Technology Officer at uBriGene Biosciences, Dr. Sun brings a wealth of expertise in the cell and gene therapy fields. With a Ph.D. from The University of British Columbia, she stands as a seasoned scientist with notable accomplishments in medicine and biotechnology, particularly in the fields of hematology and cell and gene therapy. Her prolific career is marked by the publication of over 30 academic papers in esteemed journals like PNAS, and the acquisition of 17 invention patents.

Beyond her scientific achievements, Dr. Sun demonstrates remarkable entrepreneurial acumen. She played a pivotal role in the founding of Vigene Biosciences and uBriGene, where she drove forward innovative advancements in cell and gene therapy technologies. Under her leadership, uBriGene achieved significant milestones, securing numerous international patents in areas such as viral vectors, CRISPR gene editing, and pioneering the new CGT delivery modality, mRNA/circRNA RNP.

She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property. She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property. She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property. She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property.

Mr. Li Qichen, Master of Laws from Shandong University, Senior Engineer of Pharmaceutical Engineering, served as the general manager of an investment company. In 2012, he initiated the establishment of Vigene Biosciences Inc. and served as Group Director and General Manager of China Company. In June 2021, he presided over and participated in the acquisition of Vigene Biosciences by Charles River Laboratories, a world-renowned company, for nearly $300 million. 

In 2015, as a co-founder, he founded Yiming Biotech, focusing on the preparation of GMP-level vectors for cell and gene therapy drugs. At present, the company has established a GMP production base service network serving global ATMP innovative enterprises in China and the United States, and has helped customers complete a total of 18 registration applications for IND projects in China and the United States and have been approved to enter clinical trials.

Alex Chen is the Vice President of Business Development at uBriGene Biosciences Inc. He is responsible for expanding overseas business and market share. Alex has over 20 years of experience in operational management, investment, acquisitions and strategic partnerships. 

As part of his responsibilities for managing the North American operations, he oversees corporate projects, commercial developments, and facility operations. Prior to this role, he served as Managing Director of Eastern Capital Inc., where he was responsible for USD $1 billion asset under management portfolio for an array of clients from the mining, commercial and financial services industries. 

He was also an acting advisor on an investment project for issuing USD $500 million bond for a pharmaceutical company which was listed on the Hong Kong Stock Exchange. Alex also held several leadership positions at Rio Tinto Alcan, RCI Capital Inc., Ministry of Transportation and Infrastructure BC, Worley Parsons and Westmar Advisors. He holds a BSc in Civil Engineering from Hunan University and a Master of Engineering degree from the University of British Columbia (UBC).

Dr. Hung is a serial entrepreneur and technologist. Dr. Hung was the General Manager and Chief Commercial Officer of Vigene Biosciences, a leading gene delivery company that was acquired by CRL in July 2021 for $292 Million. Prior to that Dr. Hung helped grow GenScript and SABiosciences to IPO and M&A stage, respectively.

Dr. Hung is the CEO and CoFounder of Accufy Diagnostics, an emerging leader in NGS-based multiomic analysis for MRD diagnosis and other applications. He is the co-inventor of Accufy Diagnostics patents.

Dr. Hung was a lead author for A-Gene book on AAV-based gene therapy by Alliance of Regenerative Medicine. In addition, Dr. Hung is the author of multiple patents, per reviewed publications and book chapters. Dr. Hung earned his PhD from Cornell University, MBA from UC Berkeley, and BS from Peking University.

Guoan Wang is currently Director of Process Development. He joined uBriGene from Innoforce Biopharmaceuticals, where, for three years, he built and led process research and development teams for gene therapy products including plasmid DNA, mRNA, viral vectors (AAV and LV) and non-viral vectors (LNP).

Before that, he was Director of Plasmid Production at Vigene Biosciences, where he spent three years leading the plasmid DNA business before its acquisition by Charles River Laboratory. He has a Ph.D degree in Biochemistry from Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences and had six years of postdoctoral training at NIH, Yale and MIT. His long industrial experience also includes research and development of Molecular Biological products, partly supported by multiple NIH SBIR awards.

Gavin has over 15 years of experience in biotechnology, with a focus on cancer immunotherapy, cell therapy process development, and CMC. Before joining uBriGene, he built AffyImmune’s CMC team, leading a CAR-T product through Phase 1 manufacturing and QC release, and driving the tech transfer to a CDMO for Phase 2 readiness. 

Gavin also led process and assay development for Simcere Pharmaceutical’s first allogeneic CAR-NK product and spearheaded the development of novel cell therapy pipelines from platform building to clinical manufacturing, including his work at MustangBio, where he helped transfer Mustang’s first CAR-T and gene therapy product for clinical trials. He earned his Ph.D. from Peking University and completed his postdoctoral fellowship at UC San Francisco.

Mark Sye has over 25 years of experience in supporting and enhancing GMP operations, demonstrating a decisive leadership style and a strategic approach to decision-making. He is well-versed in business practices within the biopharmaceutical industry and is recognized as a motivational leader and effective problem-solver. Mark possesses advanced skills in supervision, team building, and customer service.

His problem-solving abilities, utilizing a risk-based approach and Six Sigma tools, have successfully led to regulatory inspection approvals. Before joining uBriGene, Mark held leadership positions at Catalent, MacroGenics, GSK, Baxter Bioscience, and Becton Dickinson Microbiology Systems. He holds a B.S. in Medical Technology from Morgan State University, along with certifications as a Black Belt in Six Sigma and in Master Lean Manufacturing.

Totally eleven years experience in regulatory affairs of biologics. Successfully submitted over 20 INDs and BLAs in various countries and regions, including FDA, NMPA, EMA, Health Canada and TGA and five expedited programs in FDA and EMA

Scott is a PhD-trained molecular & cellular biologist and business development leader. He has 9 years of experience leading biotech R&D teams and 16 years in sales, business development, strategic planning, alliance management, and corporate development. Scott has supported therapeutic discovery and development across many modalities, including small molecules, biologics, cell and gene therapies, and genetic medicines. His passion for people and innovation has driven him to craft therapeutics development and manufacturing solutions that improve business efficiencies, strengthen partnerships, and promote business growth. Before joining uBriGene, Scott held leadership roles of increasing responsibility at QIAGEN, DiscoverX, FUJIFILM Cellular Dynamics Inc., Synthego, and Maravai LifeSciences.

Scott completed a postdoctoral fellowship at St Jude Children’s Research Hospital. He earned his PhD from the Indiana University School of Medicine, his Masters from Northwestern University, and his Bachelors from Purdue University.

High-achieving product Marketing Director with 10+ years of progressive experience in life sciences and cell and gene therapy CDMO services, with a strong molecular and cell biology scientific background. Seeking to contribute expertise in strategic marketing, content creation, and new product launch to a leading life sciences company.

Boon Hwa has more than 10 yrs of process development, technology transfer and manufacturing experience in autologous and allogeneic CGT products. Having manufactured several PSC MCB and WCB, process development of CAR T-cells in the Cocoon Platform at Lonza, she can take on any challenges in the complex CGT manufacturing. Her highly experienced PD and MSAT teams aim to simplify, innovate and de-risk the manufacturing processes. She is passionate and dedicated to advancing cell therapy GMP manufacturing processes from the clinical to the commercial stage. She holds a Ph.D. in Physiology from New York Medical College.